‘Drug Dealers In Nice Suits’: Sackler Family Faces Charges For Abuse Of Opioids

Overdose antidote Naloxone Hydrochloride Image by Getty Images

By Alyssa Fisher November 20, 2018

Members of the multi-billionaire Sackler family, who own the company that makes the prescription painkiller OxyContin, are facing prosecution and likely a criminal investigation over America’s devastating opioid crisis, The Guardian reported.

Connecticut-based Purdue Pharma created and sells OxyContin, a legal narcotic that kills almost 200 people a day.

Several family members were recently sued by Suffolk County in New York for the overdose deaths and addiction hitting communities. Lawyers believe other U.S. cities, counties and states will soon follow.

Prosecutors in Connecticut and New York might also be considering criminal fraud and racketeering charges, as the drug has been overprescribed and falsely marketed to doctors, legal counsel told the Guardian.

Purdue itself is also being sued by at least 30 states. Lawyers believe it will end in a massive settlement.

Paul Hanly, a New York City lawyer representing Suffolk County, described the Sacklers as a drug family.

“Drug dealers in nice suits and dresses,” he said.

Brothers Mortimer and Raymond Sackler, both of whom have died, started Purdue Pharma and created OxyContin in the mid-1990s, according to the Guardian. Out of the 20 family members, eight are listed in the lawsuit: their adult children — Richard, Jonathan, Kathe, Mortimer David Alfons Sackler and Ilene Sackler Lefcourt — and widows, Theresa and Beverly Sackler.

Alyssa Fisher is a news writer at the Forward. Email her at [email protected], or follow her on Twitter at @alyssalfisher

A message from our Publisher & CEO Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

The coming year promises to be filled with more complex and historic developments. We are entering an era where independent, fact-based Jewish journalism will be more important than ever. We need to be ready for whatever 2025 will bring, and with your help, we can be.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

— Rachel Fishman Feddersen, Publisher and CEO